7 jobs found in Youngstown, OH

This is a field-based role covering parts of Pennsylvania, Ohio, and New York. The Parkinson’s Disease (PD) Senior Manager (SM) is responsible for maximizing business opportunities with approved on-market products (drug device combination) for the Parkinson’s Franchise. The PD SM will report to the Regional Sales Director, Parkinson’s, and will have 6-8 Account Executives as direct reports.  The PD SM, and respective team, will develop and maintain strategic business relationships with accounts through interactions with approved Movement Disorder Specialists, Neurologists, Advance Practice Providers, Health Care Professionals, nurses, executive level personnel, department managers, and various other support staff. Business relationships will focus on increasing education on product benefits/risks and awareness of current therapeutic gaps, consistent with approved labels, developing new business and expand current business, maximizing resource utilization, and increasing sales...

Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can progress to cirrhosis, liver failure, need for liver transplantation and premature mortality. Every member of our Madrigal team is connected by our shared purpose: leading the fight against MASH.   Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c).   Our success is driven by our people. We are building a dynamic, inclusive, and high-performing culture that values scientific excellence, operational rigor, and collaboration. To...

Regional Business Director Opportunity with a privately held, well funded MedTech company scaling in the US: Competitive Salary and MBO Commission Structure Uncapped Variable commission opportunity Additional compensation and Equity grant potential based on performance Full benefits package with 401K Match Well funded market moving potential opportunity Commercially proven product experience and adoption Solid Executive leadership team experience Huge Market Potential for quick and sustained adoption All Laparoscopic Specialties: GYN, Urology, General Surgery, Bariatric, Colorectal Average Laparoscopic Surgeon does 300 Procedures / Year

Position Summary   The Area Sales Director – Plastics & Regenerative Medicine is a senior commercial leader responsible for driving regional growth, expanding market share, and leading a high-performing sales organization in aesthetics and reconstruction. This role requires a strategic, hands-on leader with deep experience in hospital-based medical device sales, hospital contracting and access, and building trusted relationships across surgeons, healthcare professionals, and complex health systems. The ideal candidate brings a strong business-owner mindset, combining commercial discipline, data-driven decision making, and the ability to inspire accountability and execution across teams and cross-functional partners. This leader will also be responsible for developing talent, strengthening performance, and delivering sustained business results in a competitive environment. Primary Objectives · Deliver revenue growth, market share expansion, and profitable performance across...

Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can progress to cirrhosis, liver failure, need for liver transplantation and premature mortality. Every member of our Madrigal team is connected by our shared purpose: leading the fight against MASH.   Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c).   Our success is driven by our people. We are building a dynamic, inclusive, and high-performing culture that values scientific excellence, operational rigor, and collaboration. To...

Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can progress to cirrhosis, liver failure, need for liver transplantation and premature mortality. Every member of our Madrigal team is connected by our shared purpose: leading the fight against MASH.   Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c).   Our success is driven by our people. We are building a dynamic, inclusive, and high-performing culture that values scientific excellence, operational rigor, and collaboration. To...

Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can progress to cirrhosis, liver failure, need for liver transplantation and premature mortality. Every member of our Madrigal team is connected by our shared purpose: leading the fight against MASH.   Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c).   Our success is driven by our people. We are building a dynamic, inclusive, and high-performing culture that values scientific excellence, operational rigor, and collaboration. To...